MedAdvisor Equity Ratio
Delisted
The Equity Ratio of MedAdvisor (MDR.AX) as of Oct 8, 2026 is 2.63 %. In the previous year, Equity Ratio was 52.22 % — a change of -94.96% (lower).
Get this data via API
Financial Data API
Equity Ratio
2.63 %
YoY
-94.96%
Last updated:
Equity Ratio of MedAdvisor is 2025 2.63 % . Equity Ratio of MedAdvisor was 2024 52.22 % . It decreases by -94.96% lower compared to the previous year.
The MedAdvisor Equity Ratio history
3 Years
10 Years
25 Years
Max
Equity Ratio
Date
Equity Ratio
Jan 1, 2018
87.28 AUD
Jan 1, 2019
73.42 AUD
Jan 1, 2020
78.33 AUD
Jan 1, 2021
59.87 AUD
Jan 1, 2022
44.04 AUD
Jan 1, 2023
50.53 AUD
Jan 1, 2024
52.22 AUD
Jan 1, 2025
2.63 AUD
| YEAR | Equity Ratio | YoY |
|---|---|---|
| 2.63 % | -94.96% | |
| 52.22 % | +3.34% | |
| 50.53 % | +14.73% | |
| 44.04 % | -26.44% | |
| 59.87 % | -23.56% | |
| 78.33 % | +6.69% | |
| 73.42 % | -15.88% | |
| 87.28 % | +3.56% | |
| 84.28 % | +24.68% | |
| 67.60 % | +1,538.84% | |
| 4.12 % | -90.55% | |
| 43.66 % | — |
Access this data via the Eulerpool API
MedAdvisor Stock analysis
What does MedAdvisor do? Medadvisor Ltd is an Australian company that offers a digital platform for healthcare. Founded in 2012 by Robert Read, David Liu, and Josh Swinnerton, their aim was to develop a platform that simplifies medication management for patients, pharmacies, and doctors. Today, Medadvisor is a publicly traded company with a wide range of digital healthcare solutions. They offer various solutions to support patients in medication intake and management, such as a mobile application that allows patients to manage their medications, order prescriptions, and receive reminders. They also offer solutions for pharmacies, including an online ordering system and access to electronic patient history, as well as a platform for doctors to electronically issue prescriptions. One of their latest products is a mobile application that facilitates the handling of COVID-19, providing real-time virus spread tracking and symptom tracking tools. Medadvisor focuses on meeting customer needs and continuously improving the healthcare process. They recently partnered with Take2 Healthcare to expand their range of solutions and create the best offering of health solutions. Overall, Medadvisor plays an important role in the Australian healthcare system by helping their customers live happier and healthier lives through innovative technologies and services. MedAdvisor is one of the most popular companies on Eulerpool.
Frequently Asked Questions about MedAdvisor stock
Equity Ratio of MedAdvisor is 2.63 % in 2025.
Equity Ratio of MedAdvisor changed from 52.22 % to 2.63 %, representing a -94.96% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Equity Ratio MedAdvisor since 2006 – with annual values, charts, and detailed analysis.
The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's MedAdvisor with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
Leverage — MedAdvisor
All Key Metrics — MedAdvisor
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth